Affimed N.V. (AFMD)
| Market Cap | 759.10M |
| Revenue (ttm) | 34.59M |
| Net Income (ttm) | -50.45M |
| Shares Out | 119.73M |
| EPS (ttm) | -0.43 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 455,444 |
| Open | 6.40 |
| Previous Close | 6.34 |
| Day's Range | 6.35 - 6.60 |
| 52-Week Range | 3.09 - 11.74 |
| Beta | 2.65 |
| Analysts | Strong Buy |
| Price Target | 14.75 (+123.8%) |
| Est. Earnings Date | Nov 9, 2021 |
About AFMD
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, which has completed Phase II clinical study of CD30-positive T-cell lymphoma, and hodgkin lymphoma (HL), as well as is in Phase II clinical trials for peripheral T-cell lymphoma, and transformed mycosis fungoides; that is in Phase I clinical study in combination with adoptive NK cells for CD30-postive lymphomas; and has completed Phase Ib clinical s...
Financial Performance
In 2020, Affimed N.V.'s revenue was 28.36 million, an increase of 32.58% compared to the previous year's 21.39 million. Losses were -41.37 million, 27.8% more than in 2019.
Financial numbers in millions EURFinancial StatementsAnalyst Forecast
According to 4 analysts, the average rating for Affimed N.V. stock is "Strong Buy." The 12-month stock price forecast is 14.75, which is an increase of 123.79% from the latest price.
News
New Strong Sell Stocks for September 13th
AFMD, DZSI, GMBL, NTRB, and SURF have been added to the Zacks Rank #5 (Strong Sell) List on September 13, 2021.
Affimed N.V. (AFMD) Reports Q2 Loss, Lags Revenue Estimates
Affimed N.V. (AFMD) delivered earnings and revenue surprises of -171.43% and -13.79%, respectively, for the quarter ended June 2021.
Affimed Reports Second Quarter 2021 Financial Results and Highlights Operational Progress
HEIDELBERG, Germany, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, toda...
Affimed to Present at Upcoming Investor Conferences
HEIDELBERG, Germany, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today...
Affimed to Report Second Quarter 2021 Financial Results & Corporate Update on September 8, 2021
HEIDELBERG, Germany, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today...
Will Affimed N.V. (AFMD) Report Negative Q2 Earnings?
Affimed N.V. (AFMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Affimed Announces Publication of Comprehensive Preclinical Data Demonstrating the Therapeutic Potential of AFM24 in E...
HEIDELBERG, Germany, July 30, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, annou...
3 Former Penny Stocks With Bullish Analysts & Price Targets Up To 120%
Former penny stocks biotech analysts are bullish on right now. The post 3 Former Penny Stocks With Bullish Analysts & Price Targets Up To 120% appeared first on Penny Stocks to Buy, Picks, News and Info...
3 Biotech Stocks That Could Double Soon
Wall Street analysts following these drugmakers think they can produce big gains in a short time frame.
Affimed Reports First Quarter 2021 Financial Results and Highlights Operational Progress
HEIDELBERG, Germany, July 01, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today...
Affimed Earnings Preview
Affimed (NASDAQ:AFMD) announces its next round of earnings this Thursday, July 01. Here is Benzinga's look at Affimed's Q1 earnings report.
Affimed to Report First Quarter 2021 Financial Results & Corporate Update July 1, 2021
HEIDELBERG, Germany, June 22, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today...
Affimed Announces Appointment of Uta Kemmerich-Keil to its Supervisory Board
HEIDELBERG, Germany, June 16, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today...
Affimed to Present at the Jefferies Virtual Healthcare Conference 2021
Heidelberg, Germany, May 26, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its...
Affimed Announces Virtual Annual General Meeting of Shareholders
Heidelberg, Germany, May 20, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its...
Affimed's AFM13 In Combination With NK Cells Show Improved Tumor Recognition, Killing In Preclinical Studies
Affimed NV (NASDAQ: AFMD) has announced the publication of in vitro and in vivo research of its lead innate cell engager (ICE), AFM13 (CD16A/CD30), combined with healthy donor-derived Natural killer (NK...
Could Affimed Be a Millionaire-Maker Stock?
This biotech stock has already produced some big returns this year.
Affimed Announces Publication of Preclinical Data in Clinical Cancer Research Supporting Therapeutic Potential of AFM...
AFM13 in combination with natural killer (NK) cells demonstrated improved tumor recognition and enhanced tumor cell killing in vitro and in vivo.
Affimed (AFMD) Enters Overbought Territory
Affimed (AFMD) has moved higher as of late, but there could definitely be trouble on the horizon for this company
Why Affimed N.V. Stock Dropped Today
The company's latest quarterly update was less than impressive.
Affimed Reports 2020 Financial Results and Highlights Recent Operational Progress
Heidelberg, Germany, April 15, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financi...
Affimed Highlights the Potential of its Innate Cell Engager AFM24 as EGFR-targeting Therapy for Solid Tumors as Monot...
Heidelberg, Germany, April 12, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announces pre-clinical...
Here's Why Shares of Affimed Skyrocketed Today
A 100% response rate is impressive, albeit in just four patients.
Affimed Stock Jumps After Natural Killer Cells With AFM13 Show Clinical Responses, Minimal Toxicity
Affimed NV (NASDAQ: AFMD) has announced initial clinical data from an investigator-sponsored study evaluating cord blood-derived natural killer (cbNK) cells pre-complexed with Affimed's innate cell enga...
